TW202309039A - 用於靶向布魯頓氏酪胺酸激酶降解之化合物 - Google Patents
用於靶向布魯頓氏酪胺酸激酶降解之化合物 Download PDFInfo
- Publication number
- TW202309039A TW202309039A TW111116998A TW111116998A TW202309039A TW 202309039 A TW202309039 A TW 202309039A TW 111116998 A TW111116998 A TW 111116998A TW 111116998 A TW111116998 A TW 111116998A TW 202309039 A TW202309039 A TW 202309039A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- membered monocyclic
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184439P | 2021-05-05 | 2021-05-05 | |
| US63/184,439 | 2021-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202309039A true TW202309039A (zh) | 2023-03-01 |
Family
ID=82115630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111116998A TW202309039A (zh) | 2021-05-05 | 2022-05-05 | 用於靶向布魯頓氏酪胺酸激酶降解之化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240287076A1 (enExample) |
| EP (1) | EP4333899A1 (enExample) |
| JP (1) | JP2024519496A (enExample) |
| KR (1) | KR20240017814A (enExample) |
| CN (1) | CN117580592A (enExample) |
| AR (1) | AR125768A1 (enExample) |
| AU (1) | AU2022268977A1 (enExample) |
| BR (1) | BR112023023065A2 (enExample) |
| CA (1) | CA3217417A1 (enExample) |
| CL (1) | CL2023003258A1 (enExample) |
| CO (1) | CO2023016743A2 (enExample) |
| IL (1) | IL308219A (enExample) |
| JO (1) | JOP20230274A1 (enExample) |
| MX (1) | MX2023013046A (enExample) |
| TW (1) | TW202309039A (enExample) |
| UY (1) | UY39756A (enExample) |
| WO (1) | WO2022235945A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3060629T3 (en) * | 2019-10-30 | 2026-03-27 | Biogen Ma Inc | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| KR20250020448A (ko) | 2022-06-02 | 2025-02-11 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Bcl6을 억제하거나 분해하는 화합물 및 의약학에서의 응용 |
| KR20250135228A (ko) | 2023-01-09 | 2025-09-12 | 몬테 로사 테라퓨틱스 아게 | Vav1의 표적 분해 |
| WO2024245443A1 (zh) * | 2023-06-01 | 2024-12-05 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| JP2026524477A (ja) | 2023-06-30 | 2026-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｋｒａｓの分解のためのヘテロ二官能性化合物 |
| CN122206684A (zh) | 2023-06-30 | 2026-06-12 | 默克专利有限公司 | 用于kras蛋白降解的异双功能化合物 |
| TW202510854A (zh) | 2023-08-03 | 2025-03-16 | 大陸商西藏海思科製藥有限公司 | 多環並環btk降解劑及其在醫藥上的應用 |
| EP4763845A1 (en) | 2023-08-17 | 2026-06-24 | Haisco Pharmaceutical Group Co., Ltd. | Cyano aromatic ring derivative and pharmaceutical use thereof |
| US20260028345A1 (en) | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| WO2026021570A1 (en) * | 2024-07-26 | 2026-01-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Btk degrader and use thereof |
| WO2026078542A1 (en) * | 2024-10-07 | 2026-04-16 | Dana-Farber Cancer Institute, Inc. | Janus kinase 2 degraders |
| US20260146050A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes |
| WO2026136866A1 (en) | 2024-12-20 | 2026-06-25 | Prelude Therapeutics Incorporated | Kat6 targeting compounds |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| UY37559A (es) * | 2017-01-06 | 2018-05-31 | Pharmacyclics Llc | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP3634960A1 (en) | 2017-06-09 | 2020-04-15 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019023553A1 (en) | 2017-07-28 | 2019-01-31 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| EP3774804A1 (en) * | 2018-03-26 | 2021-02-17 | Novartis AG | N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives |
| CN111936501B (zh) * | 2018-03-26 | 2023-09-22 | 诺华股份有限公司 | 布鲁顿酪氨酸激酶降解剂 |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| US12178093B2 (en) * | 2019-09-20 | 2024-12-24 | Semiconductor Energy Laboratory Co., Ltd. | Display apparatus, display module, and electronic device |
| ES3060629T3 (en) * | 2019-10-30 | 2026-03-27 | Biogen Ma Inc | Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase |
| ES3055177T3 (en) * | 2019-10-30 | 2026-02-10 | Biogen Ma Inc | Condensed pyridazine or pyrimidine as btk inhibitors |
| CN116194453A (zh) | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
| EP4146655A4 (en) * | 2020-04-30 | 2024-07-31 | BeiGene, Ltd. | DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE |
-
2022
- 2022-05-05 US US18/289,438 patent/US20240287076A1/en active Pending
- 2022-05-05 WO PCT/US2022/027888 patent/WO2022235945A1/en not_active Ceased
- 2022-05-05 IL IL308219A patent/IL308219A/en unknown
- 2022-05-05 AU AU2022268977A patent/AU2022268977A1/en active Pending
- 2022-05-05 CA CA3217417A patent/CA3217417A1/en active Pending
- 2022-05-05 UY UY0001039756A patent/UY39756A/es unknown
- 2022-05-05 CN CN202280047793.5A patent/CN117580592A/zh active Pending
- 2022-05-05 JP JP2023567962A patent/JP2024519496A/ja active Pending
- 2022-05-05 AR ARP220101179A patent/AR125768A1/es unknown
- 2022-05-05 KR KR1020237041952A patent/KR20240017814A/ko active Pending
- 2022-05-05 EP EP22731839.1A patent/EP4333899A1/en active Pending
- 2022-05-05 BR BR112023023065A patent/BR112023023065A2/pt unknown
- 2022-05-05 MX MX2023013046A patent/MX2023013046A/es unknown
- 2022-05-05 TW TW111116998A patent/TW202309039A/zh unknown
-
2023
- 2023-10-31 JO JOJO/P/2023/0274A patent/JOP20230274A1/ar unknown
- 2023-11-02 CL CL2023003258A patent/CL2023003258A1/es unknown
- 2023-12-01 CO CONC2023/0016743A patent/CO2023016743A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023013046A (es) | 2023-12-15 |
| CO2023016743A2 (es) | 2023-12-29 |
| KR20240017814A (ko) | 2024-02-08 |
| CN117580592A (zh) | 2024-02-20 |
| AR125768A1 (es) | 2023-08-09 |
| US20240287076A1 (en) | 2024-08-29 |
| BR112023023065A2 (pt) | 2024-01-30 |
| JP2024519496A (ja) | 2024-05-14 |
| EP4333899A1 (en) | 2024-03-13 |
| WO2022235945A1 (en) | 2022-11-10 |
| CA3217417A1 (en) | 2022-11-10 |
| UY39756A (es) | 2022-11-30 |
| JOP20230274A1 (ar) | 2023-10-31 |
| CL2023003258A1 (es) | 2024-05-03 |
| AU2022268977A1 (en) | 2023-11-30 |
| IL308219A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024519496A (ja) | ブルトンのチロシンキナーゼの分解を標的化するための化合物 | |
| CN112707893B (zh) | 作为usp30抑制剂的1-氰基吡咯烷化合物 | |
| JP6976953B2 (ja) | Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物 | |
| US11897900B2 (en) | Inhibitors of KEAP1-Nrf2 protein-protein interaction | |
| AU2019228568B2 (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates | |
| KR20230040991A (ko) | Braf 분해제 | |
| TW202237597A (zh) | 新型egfr降解劑 | |
| MX2014002482A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| EA015488B1 (ru) | Содержащие диариловый эфир соединения мочевины | |
| CN116783199A (zh) | 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物 | |
| KR20210106441A (ko) | 사이클릭 우레아 | |
| TW202140499A (zh) | 巨環ｒｉｐ２－激酶抑制劑 | |
| JP2024544529A (ja) | Ｂｔｋ阻害剤 | |
| JP7734147B2 (ja) | Ｓｓｔｒ４アゴニストとしてのｎ－（ヘテロシクリル及びヘテロシクリルアルキル）－３－ベンジルピリジン－２－アミン誘導体 | |
| TW202220972A (zh) | Ｂｔｋ抑制劑 | |
| CN116635028A (zh) | c-MYC mRNA翻译调节剂及其在治疗癌症中的用途 | |
| CA3108534C (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| OA21863A (en) | Indazole based compounds and associated methods of use. | |
| CN117957225A (zh) | 用于靶向irak4蛋白的降解的化合物 | |
| HK40054771B (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| HK40054771A (en) | Inhibitors of keap1-nrf2 protein-protein interaction |